|
PARP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.71889999906116E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.3053999998488E-07 |
| Normal-vs-Stage2 |
1.55284999999727E-05 |
| Normal-vs-Stage3 |
1.65390999999904E-05 |
| Normal-vs-Stage4 |
6.16320000035309E-07 |
| Stage1-vs-Stage2 |
3.097800E-01 |
| Stage1-vs-Stage3 |
8.035800E-01 |
| Stage1-vs-Stage4 |
3.266000E-01 |
| Stage2-vs-Stage3 |
4.786400E-01 |
| Stage2-vs-Stage4 |
9.418400E-01 |
| Stage3-vs-Stage4 |
4.562200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.45200000029244E-07 |
| Normal-vs-AfricanAmerican |
3.611500E-04 |
| Normal-vs-Asian |
2.284300E-02 |
| Caucasian-vs-AfricanAmerican |
6.590400E-01 |
| Caucasian-vs-Asian |
5.349600E-02 |
| AfricanAmerican-vs-Asian |
9.423700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.54149999998366E-07 |
| Normal-vs-Female |
9.75370000322329E-08 |
| Male-vs-Female |
9.846800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.1892999997083E-07 |
| Normal-vs-Age(41-60Yrs) |
4.8690999999712E-06 |
| Normal-vs-Age(61-80Yrs) |
3.80919999987128E-08 |
| Normal-vs-Age(81-100Yrs) |
1.024080E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.349400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.934600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.926200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.936430E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.284400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.883600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.090220E-01 |
| Classical-VS-Follicular |
1.78402999999605E-05 |
| Classical-VS-Other |
4.465400E-01 |
| Classical-VS-Normal |
2.15339999999342E-05 |
| Tall-VS-Follicular |
1.736430E-01 |
| Tall-VS-Other |
9.578400E-01 |
| Tall-VS-Normal |
7.91549999999974E-05 |
| Follicular-VS-Other |
4.455400E-01 |
| Follicular-VS-Normal |
1.27010002515249E-09 |
| Other-VS-Normal |
3.031800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.37829999968808E-07 |
| Normal-vs-N1 |
8.28440000000263E-05 |
| N0-vs-N1 |
6.979600E-01 |
|
|
